Bukys Michael A, Orban Tivadar, Kim Paul Y, Nesheim Michael E, Kalafatis Michael
Cleveland State University, Department of Chemistry, OH 44115, USA.
Thromb Haemost. 2008 Mar;99(3):511-22.
Incorporation of factor (F) Va into prothrombinase directs prothrombin activation by FXa through the meizothrombin pathway, characterized by initial cleavage at Arg(320). We have shown that a pentapeptide with the sequence DYDYQ specifically inhibits this pathway. It has been also established that Hir(54-65)(SO(3)(-)) is a specific inhibitor of prothrombinase. To understand the role of FVa within prothrombinase at the molecular level, we have studied thrombin formation by prothrombinase in the presence of various prothrombin-derived fragments alone or in combination. Activation of prethrombin 1 is slow with cleavages at Arg(320) and Arg(271) occurring with similar rates. Addition of purified fragment 1 to prethrombin 1 accelerates both the rate of cleavage at Arg(320) and thrombin formation. Both reactions were inhibited by Hir(54-65)(SO(3)(-)) while DYDYQ had no significant inhibitory effect on prethrombin 1 cleavage in the absence or presence of fragment 1. Similarly, activation of prethrombin 2 by prothrombinase, is inhibited by Hir(54-65)(SO(3)(-)), but is not affected by DYDYQ. Addition of purified fragment 12 to prethrombin 2 accelerates the rate of cleavage at Arg(320) by prothrombinase. This addition also results in a significant inhibition of thrombin formation by DYDYQ and is concurrent with the elimination of the inhibitory effect of Hir(54-65)(SO(3)(-)) on the same reaction. Finally, a membrane-bound ternary complex composed of prethrombin 2/fragment 12/Hir(54-65)(SO(3)(-)) is inhibited by DYDYQ. Altogether, the data demonstrate that membrane-bound fragment 1 is required to promote optimum Fva cofactor activity which in turn is translated by efficient initial cleavage of prothrombin by prothrombinase at Arg(320).
将因子(F)Va掺入凝血酶原酶可通过中凝血酶途径指导FXa对凝血酶原的激活,其特征是在精氨酸(320)处开始裂解。我们已经表明,序列为DYDYQ的五肽可特异性抑制该途径。还确定了Hir(54 - 65)(SO₃⁻)是凝血酶原酶的特异性抑制剂。为了在分子水平上理解FVa在凝血酶原酶中的作用,我们研究了在单独或组合存在各种凝血酶原衍生片段的情况下,凝血酶原酶形成凝血酶的过程。凝血酶原1的激活较慢,在精氨酸(320)和精氨酸(271)处的裂解速率相似。向凝血酶原1中添加纯化的片段1可加速在精氨酸(320)处的裂解速率和凝血酶的形成。这两个反应均被Hir(54 - 65)(SO₃⁻)抑制,而在不存在或存在片段1的情况下,DYDYQ对凝血酶原1的裂解没有显著抑制作用。同样,凝血酶原酶对凝血酶原2的激活被Hir(54 - 65)(SO₃⁻)抑制,但不受DYDYQ影响。向凝血酶原2中添加纯化的片段12可加速凝血酶原酶在精氨酸(320)处的裂解速率。这种添加还导致DYDYQ对凝血酶形成的显著抑制,并且与消除Hir(54 - 65)(SO₃⁻)对同一反应的抑制作用同时发生。最后,由凝血酶原2/片段12/Hir(54 - 65)(SO₃⁻)组成的膜结合三元复合物被DYDYQ抑制。总之,数据表明膜结合的片段1是促进最佳Fva辅因子活性所必需的,而这又通过凝血酶原酶在精氨酸(320)处对凝血酶原的有效初始裂解来实现。